News

The National Institute for Health and Care Excellence3d
10 Year Health Plan empowers NICE to get patients better care, faster
The 10-Year Health Plan marks a significant step forward in building an NHS that is faster, fairer and fit for the future. At NICE, we’re ready to deliver - using our expanded remit to accelerate ...
National Institute for Health and Care Excellence27d
Final draft guidance | Project documents | Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over ID6221 | Guidance | NICE
The FDG has been sent to consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it and/or notify us of any factual errors. The FDG has been sent to ...
National Institute for Health and Care Excellence7d
Technology appraisal committee meeting (committee B) - NICE
02 July 2025 Zoom Draft Agenda The meeting will take place as a meeting via Zoom, a secure web conferencing tool. This meeting will run from 9:00am to 5:00pm, although timings may be subject to change ...
National Institute for Health and Care Excellence21d
Spesolimab for treating generalised pustular psoriasis flares
Evidence-based recommendations on spesolimab (Spevigo) for treating generalised pustular psoriasis flares in adults. Last reviewed: 18 June 2025 Next review: This guidance will be reviewed if there is ...
National Institute for Health and Care Excellence29d
Updated guideline to increase access to treatments for early-stage chronic heart failure could reduce deaths and hospital admissions by thousands | NICE
Our updated guideline reflects this change in practice and in doing so they recommend an earlier use of the SGLT2 inhibitors empagliflozin and dapagliflozinthan we’ve recommended before. It means they ...
National Institute for Health and Care Excellence20d
Final draft guidance finds benefits of 2 Alzheimer’s treatments remain too small to justify the additional costs to the NHS | NICE
This means the medicines should not be provided on the NHS as they are not good value for money. Last month the appraisal committee met to consider new information submitted as part of its additional ...
National Institute for Health and Care Excellence27d
Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [ID6212] - NICE
Home NICE Guidance Conditions and diseases Blood and immune system conditions Blood and bone marrow cancers Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory ...
National Institute for Health and Care Excellence26d
NICE leads the way in approving breakthrough treatment for multiple myeloma
Around 1,500 people with multiple myeloma are set to benefit from the treatment, which combines belantamab mafodotin (brand name Blenrep) with bortezomib and dexamethasone. The guidance recommends the ...
National Institute for Health and Care Excellence20d
Overview | Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer | Guidance | NICE
Evidence-based recommendations on atezolizumab (Tecentriq) for the adjuvant treatment of resected non-small-cell lung cancer in adults. Last reviewed: 19 June 2025 Next review: This guidance will be ...
National Institute for Health and Care Excellence20d
Overview | Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) | Guidance | NICE
NICE is unable to make a recommendation on tislelizumab (Tevimbra) for treating advanced non-small-cell lung cancer after platinum-based chemotherapy in adults. This is because BeiGene withdrew its ...
National Institute for Health and Care Excellence20d
Overview | Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessment | Guidance | NICE
Late stage assessment (LSA) guidance on topical antimicrobial dressings for locally infected leg ulcers. Last reviewed: 19 June 2025 Guidance development process LSA guidance evaluates categories of ...